Skip to content

PTHS PTHS License — Contractual Obligation

Other product segments

Reedy Creek Purchase Agreement
$20.87M
ZELSUVMI Royalty Agreement
$10.2M
Xepi Royalty Agreement
$2.22M
Amended Sato license
$1.13M
Channel Products Royalty Agreement
$0

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNLicense — Contract Liabilities
$90M
Zevra Therapeutics, Inc. logo
ZVRALicense — Contract with customer, liability
$0
Nuvation Bio logo
NUVBLicense — Deferred Revenue
$58.7M
CTO
CTORLicense Payable
$17.65M-37.9%
FOS
FOSLLicensing Income — Contract Liabilities
$300K
Allogene Therapeutics logo
ALLOLicense — Revenue, remaining performance obligation, amount
$4.6M0.0%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:ContractualObligation.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's license — contractual obligation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's license — contractual obligation?
PTHS (PTHS) reported license — contractual obligation of $35.07M in Q1 2026.
What does license — contractual obligation mean?
Represents the total outstanding financial commitment arising from licensing agreements for intellectual property or technology rights. This metric captures the aggregate liability the company is obligated to pay to licensors over the life of the contract to maintain access to essential therapeutic assets.